Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
तुलना करने के लिए मीट्रिक्स | LXRX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधLXRXपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −1.2x | −2.2x | −0.6x | |
PEG अनुपात | −0.51 | −0.01 | 0.00 | |
क़ीमत/बुक | 1.4x | 1.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 48.7x | 13.6x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 171.7% | 327.3% | 44.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 8.5% | 7.3% | अनलॉक करें |